BFM
ORMP icon

Boothbay Fund Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Boothbay Fund Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.78M Sell
578,638
-22,078
-4% -$87.9K 0.04% 571
2026
Q1 		$2.04M Sell
600,716
-11,444
-2% -$38.8K 0.03% 609
2025
Q4 		$1.74M Sell
612,160
-233,231
-28% -$602K 0.03% 604
2025
Q3 		$2.23M Hold
845,391
– – 0.03% 540
2025
Q2 		$1.9M Sell
845,391
-97
-0% -$214 0.04% 517
2025
Q1 		$1.81M Buy
845,488
+300
+0% +$692 0.05% 451
2024
Q4 		$2.05M Buy
845,188
+16,857
+2% +$40.1K 0.05% 441
2024
Q3 		$2.02M Buy
828,331
+3,333
+0.4% +$8.13K 0.05% 515
2024
Q2 		$2.12M Buy
824,998
+135,249
+20% +$321K 0.05% 477
2024
Q1 		$2.01M Buy
689,749
+164,748
+31% +$461K 0.04% 511
2023
Q4 		$1.21M Buy
+525,001
New +$1.12M 0.03% 669
2020
Q3 		– Sell
-30,963
Closed -$109K – 1162
2020
Q2 		$109K Sell
30,963
-6,110
-16% -$20.5K 0.01% 874
2020
Q1 		$113K Buy
+37,073
New +$162K 0.01% 716

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Boothbay Fund Management's ORMP Position: Q2 2026 in Review

Boothbay Fund Management reduced its Oramed Pharmaceuticals (ORMP) stake by 3.7% in Q2 2026, selling an estimated $87.9K and leaving 578,638 shares worth $2.78M. The position accounts for 0.04% of the portfolio, ranked #571.

Boothbay Fund Management first reported a position in ORMP in Q1 2020 and has held it in 13 quarters since. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Boothbay Fund Management held 578,638 shares of Oramed Pharmaceuticals worth $2.78M as of Q2 2026.
  • Boothbay Fund Management sold 22,078 Oramed Pharmaceuticals shares in Q2 2026, an estimated $87.9K.
  • Oramed Pharmaceuticals made up 0.04% of Boothbay Fund Management's portfolio in Q2 2026, its #571 holding.
  • Boothbay Fund Management first reported a position in Oramed Pharmaceuticals in Q1 2020 and has held it in 13 quarters since.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.